No coin nor oath required. For personal study only.
Bleeding, see Haemorrhage; Haemorrhagic disorders Blood group antigens and haemolytic disease of newborn, 111-12 Bone, involvement in Gaucher disease, 124-8 in thalassaemia intermedia (severe), 164-5 Bone marrow in congenital dyserythropoietic anaemias, 18 l-2, 187, 190 failure, platelet transfusion in, 228 transplantation Cancer, see Oncology Candidosis, BMT patients, 241-54 Cardiology, see Heart Cardiopulmonary bypass, platelet consumption/loss, 229-30 CD4 counts in HIV-infected haemophiliacs clotting factor concentrates and, 142 disease progression and, 136-7 CD44, erythroid, congenital dyserythropoietic anaemia with deficiency of, and novel intraerythroblast inclusions, 194 CD59,4 Central nervous system and prion protein, 259-60 Cerebral haemorrhage, oral anticoagulant-induced, 36 Chemokine receptor 5 and HIV infection, 138 Chemotherapy, 52-7 1, 201 (evrutum) in acute myeloid leukaemia, 54-6 elderly, 147-50 fungal infections associated with immunosuppression, 241-54 multi-drug resistance modifiers, 61-3 myelodysplastic syndromes caused by, 79-81 Children BMT as infection risk, 243 chronic myelomonocytic leukaemia, 77-8 Gaucher disease enzyme therapy, 127-8, 130 growth and puberty, 127-8 HIV-infected haemophiliacs having, 140-l CHOP therapy, non-Hodgkin's lymphoma, 57, 58 Chromosome 5q deletion, 77 Chromosome 17~ deletion, 78 Clotting, see Coagulation Coagulation disseminated intravascular, platelet transfusion, 230 in hyperhomocystinaemia, 3 1 Coagulation factor concentrates, see also speciJic factors in HIV-infected haemophiliacs, 142 with overanticoagulation, 38-41, 94-5 Colony stimulating factors in acute myeloid leukaemia in elderly, 148, 149 in fungal infection prophylaxis in BMT patients, 25 1 Community (in venous thrombotic disease)
๐ SIMILAR VOLUMES